Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease (ORCHESTRA)

AbbVie

Status: Enrolling

Conditions: Parkinson's Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT06937034

H25-878

Details and patient eligibility

About

Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.

Trial design

2,000 participants in 1 patient group

Participants with Parkinson's Disease

Description:

Advanced Parkinson Disease Patients treated with foslevodopa/foscarbidopa.